Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01PVV
|
|||
| Former ID |
DCL000143
|
|||
| Drug Name |
KD3010
|
|||
| Indication | Metabolic disorder [ICD-11: 5C50-5D2Z] | Phase 1 | [1] | |
| Obesity [ICD-11: 5B81; ICD-10: E66] | Phase 1 | [1] | ||
| Company |
Kalypsys
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Peroxisome proliferator-activated receptor delta (PPARD) | Target Info | Agonist | [1] |
| KEGG Pathway | PPAR signaling pathway | |||
| Wnt signaling pathway | ||||
| Pathways in cancer | ||||
| Acute myeloid leukemia | ||||
| NetPath Pathway | IL2 Signaling Pathway | |||
| Panther Pathway | Wnt signaling pathway | |||
| Pathway Interaction Database | Presenilin action in Notch and Wnt signaling | |||
| RXR and RAR heterodimerization with other nuclear receptor | ||||
| Reactome | Import of palmitoyl-CoA into the mitochondrial matrix | |||
| Regulation of pyruvate dehydrogenase (PDH) complex | ||||
| Nuclear Receptor transcription pathway | ||||
| WikiPathways | Wnt Signaling Pathway and Pluripotency | |||
| Nuclear Receptors in Lipid Metabolism and Toxicity | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Vitamin D Receptor Pathway | ||||
| Ectoderm Differentiation | ||||
| Adipogenesis | ||||
| Nuclear Receptors | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Kalypsys nearing completion of phase Ia study of KD3010 for metabolic disorders. Kalypsys. 2007. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.